1
|
Sousa C, Duarte D, Silva-Lima B, Videira M. Repurposing Natural Dietary Flavonoids in the Modulation of Cancer Tumorigenesis: Decrypting the Molecular Targets of Naringenin, Hesperetin and Myricetin. Nutr Cancer 2021; 74:1188-1202. [PMID: 34739306 DOI: 10.1080/01635581.2021.1955285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
In the past few years flavonoids have been gaining more attention regarding their (still un) exploited anticancer properties. Flavonoids are natural compounds present in fruits, vegetables, and seeds, meaning that they are already present in the daily life of every person, with a described broad-spectrum of pharmacological activities, including anticancer, anti-inflammatory and antioxidant. In the present review we discuss the anticancer activity of three important flavonoids - myricetin (MYR) (flavanol group), hesperetin (HESP) and naringenin (NAR) (flavanone group). Although some mechanisms underlying their activities remain still unclear, they can act as potential inhibitors of key tumorigenic signaling pathways, such as PI3K/Akt/mTOR, p38 MAPK and NF-κB. Simultaneously, they can reset the levels of pro-apoptotic proteins that belong to the Bcl-2 and caspase family and decrease the intracellular levels of ROS and pro-inflammatory cytokines, such as TNF-α, IL-1β and IL-6. Together with their synergetic effect they have the potential to become key elements in the prevention and/or treatment of several types of cancer, with the major improvement to the patient life quality, due to their non-existent toxicity.
Collapse
Affiliation(s)
- Carolina Sousa
- Pharmacological and Regulatory Sciences Group (PharmRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal
| | - Denise Duarte
- Pharmacological and Regulatory Sciences Group (PharmRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal
| | - Beatriz Silva-Lima
- Pharmacological and Regulatory Sciences Group (PharmRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal
| | - Mafalda Videira
- Pharmacological and Regulatory Sciences Group (PharmRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal
| |
Collapse
|
2
|
Brito MDF, Torre C, Silva-Lima B. Scientific Advances in Diabetes: The Impact of the Innovative Medicines Initiative. Front Med (Lausanne) 2021; 8:688438. [PMID: 34295913 PMCID: PMC8290522 DOI: 10.3389/fmed.2021.688438] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Accepted: 06/02/2021] [Indexed: 12/16/2022] Open
Abstract
Diabetes Mellitus is one of the World Health Organization's priority diseases under research by the first and second programmes of Innovative Medicines Initiative, with the acronyms IMI1 and IMI2, respectively. Up to October of 2019, 13 projects were funded by IMI for Diabetes & Metabolic disorders, namely SUMMIT, IMIDIA, DIRECT, StemBANCC, EMIF, EBiSC, INNODIA, RHAPSODY, BEAT-DKD, LITMUS, Hypo-RESOLVE, IM2PACT, and CARDIATEAM. In general, a total of €447 249 438 was spent by IMI in the area of Diabetes. In order to prompt a better integration of achievements between the different projects, we perform a literature review and used three data sources, namely the official project's websites, the contact with the project's coordinators and co-coordinator, and the CORDIS database. From the 662 citations identified, 185 were included. The data collected were integrated into the objectives proposed for the four IMI2 program research axes: (1) target and biomarker identification, (2) innovative clinical trials paradigms, (3) innovative medicines, and (4) patient-tailored adherence programmes. The IMI funded projects identified new biomarkers, medical and research tools, determinants of inter-individual variability, relevant pathways, clinical trial designs, clinical endpoints, therapeutic targets and concepts, pharmacologic agents, large-scale production strategies, and patient-centered predictive models for diabetes and its complications. Taking into account the scientific data produced, we provided a joint vision with strategies for integrating personalized medicine into healthcare practice. The major limitations of this article were the large gap of data in the libraries on the official project websites and even the Cordis database was not complete and up to date.
Collapse
Affiliation(s)
| | - Carla Torre
- Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.,Laboratory of Systems Integration Pharmacology, Clinical & Regulatory Science-Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal
| | - Beatriz Silva-Lima
- Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.,Laboratory of Systems Integration Pharmacology, Clinical & Regulatory Science-Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal
| |
Collapse
|
3
|
Gaspar RS, Silva-Lima B, Magro F, Alcobia A, da Costa FL, Feio J. Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision. Front Med (Lausanne) 2020; 7:590527. [PMID: 33330550 PMCID: PMC7719831 DOI: 10.3389/fmed.2020.590527] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2020] [Accepted: 09/30/2020] [Indexed: 01/07/2023] Open
Abstract
Non-Biological Complex Drugs (NBCDs) are complex non-biological drugs comprised of large high molecular weight molecules and, often, nanoparticular structures (including liposomes and block-copolymer micelles). In the case of NBCDs, the entire complex is the active pharmaceutical ingredient and its properties cannot be fully characterized by physicochemical analysis. Moreover, the manufacturing process is fundamental in creating the correct originator product. The same is true for generic versions of the product. A recent appraisal of approval procedures for NBCDs "follow-on products" approved in Europe shows a diversity of regulatory pathways. In fact, three different abridged application procedures, under European legislation, were used: the generic application procedure of Article 10(1), the hybrid application procedure of Article 10(3), and the biosimilar application procedure of Article 10(4). Three informed consent applications via Article 10(c) from innovator companies of glatiramer acetate and sevelamer carbonate were submitted shortly after the approval of the first follow-on products. Furthermore, a number of "well-established use" applications [via Article 10(a)] were approved for iron sucrose and iron dextran complexes. In order to protect patients from the increased risks of NBCD products and NBCD follow-on products, two complementary approaches should be considered: (i) improving the regulatory procedures and their guidance documents within the pre-registration phase, and (ii) not considering interchangeability whenever clinical data is not available. With regards to the latter, the need for adequate safety and efficacy data might also include risk management programmes within post-approval pharmacovigilance actions. This, however, would depend on a risk appraisal that must be considered for individual medicinal products, based on the nature of the submitted relevant set of safety/efficacy data.
Collapse
Affiliation(s)
- Rogério Sá Gaspar
- Departamento de Sócio Farmácia, Faculdade de Farmácia, Universidade de Lisboa,Lisboa, Portugal
- Institute for Biosciences and Bioengineering (iBB), Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal
| | - Beatriz Silva-Lima
- Departamento de Ciências Farmacológicas, Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal
- Research Institute for Medicines (iMed), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal
| | - Fernando Magro
- Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal
- Department of Gastroenterology, Centro Hospitalar São João, Porto, Portugal
- Center for Drug Discovery and Innovative Medicines (MedInUp), University of Porto, Porto, Portugal
- Unidade de Farmacologia Clínica, Centro Hospitalar Universitário de S. João, Porto, Portugal
| | - Armando Alcobia
- Department of Gastroenterology, Centro Hospitalar São João, Porto, Portugal
- Serviços Farmacêuticos, Hospital Garcia de Orta, Almada, Portugal
| | - Fernando Leal da Costa
- Center for Drug Discovery and Innovative Medicines (MedInUp), University of Porto, Porto, Portugal
- Instituto Português de Oncologia de Lisboa, Lisboa, Portugal
| | - José Feio
- Unidade de Farmacologia Clínica, Centro Hospitalar Universitário de S. João, Porto, Portugal
- Serviços Farmacêuticos, Centro Hospitalar Universitário de Coimbra (CHUC), Coimbra, Portugal
| |
Collapse
|
4
|
Videira MA, Llop J, Sousa C, Kreutzer B, Cossío U, Forbes B, Vieira I, Gil N, Silva-Lima B. Pulmonary Administration: Strengthening the Value of Therapeutic Proximity. Front Med (Lausanne) 2020; 7:50. [PMID: 32181253 PMCID: PMC7058098 DOI: 10.3389/fmed.2020.00050] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Accepted: 02/03/2020] [Indexed: 12/14/2022] Open
Abstract
In recent years inhaled systems have shown momentum as patient-personalized therapies emerge. A significant improvement in terms of therapeutic efficacy and/or reduction adverse systemic effects is anticipated from their use owing these systems regional accumulation. Nevertheless, whatever safety and efficacy evidence required for inhaled formulations regulatory approval, it still poses an additional hurdle to gaining market access. In contrast with the formal intravenous medicines approval, the narrower adoption of pulmonary administration might rely on discrepancies in pre-clinical and clinical data provided by the marketing authorization holder to the regulatory authorities. Evidences of a diverse and inconsistent regulatory framework led to concerns over toxicity issues and respiratory safety. However, an overall trend to support general concepts of good practices exists. Current regulatory guidelines that supports PK/PD (pharmacokinetics/pharmacodynamic) assessment seeks attention threatening those inhaled formulations set to be approved in the coming years. A more complex scenario arises from the attempt of implementing nanomedicines for pulmonary administration. Cutting-edge image techniques could play a key role in supporting diverse stages of clinical development facilitating this pharmaceutics take off and speed to patients. The ongoing challenge in adapting conventional regulatory frameworks has proven to be tremendously difficult in an environment where market entry relies on multiple collections of evidence. This paper intention is to remind us that an acceptable pre-clinical toxicological program could emerge from, but not only, an accurate and robust data imaging collection. It is our conviction that if implemented, inhaled nanomedicines might have impact in multiple severe conditions, such as lung cancer, by fulfilling the opportunity for developing tailored treatments while solving dose-related toxicity issues; the most limiting threat in conventional lung cancer clinical management.
Collapse
Affiliation(s)
- Mafalda A Videira
- Departamento de Farmácia Galénica e de Tecnologia Farmacêutica, Faculdade de Farmácia da Universidade de Lisboa, iMed.ULisboa-Research Institute for Medicines and Pharmaceutical Sciences, Lisbon, Portugal
| | - Jordi Llop
- Radiochemistry and Nuclear Imaging Group, CIC biomaGUNE, Donostia-San Sebastián, Spain
| | - Carolina Sousa
- Departamento de Farmácia Galénica e de Tecnologia Farmacêutica, Faculdade de Farmácia da Universidade de Lisboa, iMed.ULisboa-Research Institute for Medicines and Pharmaceutical Sciences, Lisbon, Portugal
| | - Bruna Kreutzer
- Departamento de Farmácia Galénica e de Tecnologia Farmacêutica, Faculdade de Farmácia da Universidade de Lisboa, iMed.ULisboa-Research Institute for Medicines and Pharmaceutical Sciences, Lisbon, Portugal
| | - Unai Cossío
- Radiochemistry and Nuclear Imaging Group, CIC biomaGUNE, Donostia-San Sebastián, Spain
| | - Ben Forbes
- Institute of Pharmaceutical Science, King's College London, London, United Kingdom
| | - Isabel Vieira
- Departamento de Farmácia Galénica e de Tecnologia Farmacêutica, Faculdade de Farmácia da Universidade de Lisboa, iMed.ULisboa-Research Institute for Medicines and Pharmaceutical Sciences, Lisbon, Portugal
| | - Nuno Gil
- Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Beatriz Silva-Lima
- Departamento de Farmácia Galénica e de Tecnologia Farmacêutica, Faculdade de Farmácia da Universidade de Lisboa, iMed.ULisboa-Research Institute for Medicines and Pharmaceutical Sciences, Lisbon, Portugal
| |
Collapse
|
5
|
van der Laan JW, Benson CT, Janssens W, Bos J, Stahl E, Brady JT, Wändel-Liminga U, Corriol-Rohou S, Forster R, Hartmann A, Pertel PE, Robertson SM, Silva-Lima B, Malik RE, Chibout SD. Shared Learnings on the New EMA First-in-Human and Early Clinical Trial Guideline: Proceedings From a DIAlogue Session at DIA Europe 2018. Ther Innov Regul Sci 2019. [DOI: 10.1177/2168479019843514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Jan Willem van der Laan
- Section on Pharmacology, Toxicology and Kinetics, Medicines Evaluation Board, Utrecht, the Netherlands
| | - Charles T. Benson
- Clinical Pharmacology—San Diego, Eli Lilly and Company, Indianapolis, IN
| | - Walter Janssens
- Federal Agency For Medicines and Health Products, Brussels, Belgium
| | - Jeroen Bos
- Regulatory Affairs, Novartis Pharma, Basel, Switzerland
| | - Elke Stahl
- Clinical Trial Unit, Federal Institute for Drugs and Medical Devices, BfArM, Bonn, Germany
| | - Joseph T. Brady
- Drug Safety Research and Development, Pfizer, INC, Cambridge, MA
| | | | | | | | | | | | | | - Beatriz Silva-Lima
- Department of Pharmacology, Universidade de Lisboa, Lisboa, Portugal
- NDA Advisory Board, UK
| | | | | |
Collapse
|
6
|
Sousa C, Gouveia LF, Kreutzer B, Silva-Lima B, Maphasa RE, Dube A, Videira M. Polymeric Micellar Formulation Enhances Antimicrobial and Anticancer Properties of Salinomycin. Pharm Res 2019; 36:83. [PMID: 30989413 DOI: 10.1007/s11095-019-2615-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Accepted: 03/24/2019] [Indexed: 12/17/2022]
Abstract
PURPOSE Salinomycin (SAL) is a polyether compound that exhibits strong antimicrobial as well as anticancer activity. Nanomedicine has been at the forefront of drug delivery research with the aim of increasing the efficacy, specificity and reduce toxicity of drugs. There is an intersection between infection and cancer, and cancer patients are prone to bacterial infections. In this study, polymeric micelles were prepared using Pluronic® F127 (PM) to encapsulate SAL (PM_SAL) with the view of enhancing antimicrobial and anticancer activity. METHODS A Quality by Design (QbD) approach was utilized to synthesize PM_SAL, and nanoformulation activity was determined against bacterial (S. aureus, MRSA and E. coli). Effects on cancer cell line A549, i.e. cell viability, prevention of P-gp efflux, vimentin expression, effects on migratory ability of A549 cells. Anticancer activity was determined by ability to eradicate cancer stem-like cells. RESULTS PM_SAL demonstrated only efficacy against MRSA, being even higher than that obtained with SAL. In A549 cells, a 15-fold increase in P-gp's expression as well as a significant decrease of the cell's migration, was observed. CONCLUSIONS PM_SAL can interfere with the oncogenic protein VIM, involved in the crucial mechanisms EMT, downregulating its expression. Altogether data obtained indicates that this antibiotic and the developed polymeric micelle system is a very promising inhibitor of tumor cell growth.
Collapse
Affiliation(s)
- Carolina Sousa
- Pharmacological and Regulatory Sciences Group (PharmaRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdadde de Farmácia da Universidade de Lisboa, Lisbon, Portugal
| | - Luís F Gouveia
- Pharmacological and Regulatory Sciences Group (PharmaRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdadde de Farmácia da Universidade de Lisboa, Lisbon, Portugal
| | - Bruna Kreutzer
- Pharmacological and Regulatory Sciences Group (PharmaRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdadde de Farmácia da Universidade de Lisboa, Lisbon, Portugal
| | - Beatriz Silva-Lima
- Pharmacological and Regulatory Sciences Group (PharmaRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdadde de Farmácia da Universidade de Lisboa, Lisbon, Portugal
| | - Retsepile E Maphasa
- Discipline of Pharmaceutics, School of Pharmacy, University of the Western Cape, Bellville, South Africa
| | - Admire Dube
- Discipline of Pharmaceutics, School of Pharmacy, University of the Western Cape, Bellville, South Africa
| | - Mafalda Videira
- Pharmacological and Regulatory Sciences Group (PharmaRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdadde de Farmácia da Universidade de Lisboa, Lisbon, Portugal.
- iMed.ULisboa - Research Institute for Medicines and Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon, Av. Professor Gama Pinto, 1649-003, Lisbon, Portugal.
| |
Collapse
|
7
|
Ponte H, Ivo RS, Silva-Lima B, Ramos F. Quality control programmes for veterinary antimicrobial medicines. Regul Toxicol Pharmacol 2018; 99:1-4. [PMID: 30130551 DOI: 10.1016/j.yrtph.2018.08.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Revised: 08/14/2018] [Accepted: 08/17/2018] [Indexed: 10/28/2022]
Abstract
The health benefits of the antimicrobial's use is inherently associated to the risk of antimicrobial resistance (AMR), an ever-increasing multifactorial problem, closely related with injudicious use of antimicrobials, and the lack of new antimicrobial medicines on the market, particularly for veterinary use. Currently, an increasing number of regulatory "One Health" action plans on AMR are running worldwide, already based on monitoring and surveillance systems for resistance and antimicrobials consumption. Such plans are still not mandatory in the European Union member States (EU-MS), but post marketing annual programmes for quality controls of medicines are, to verify and ensure full compliance with the marketing authorizations. The European "risk level" sampling is not based on the conventional risk-ranking process of severity factors vs the probability of occurrence, but instead, on the conviction that in the European Union (EU) all medicines are produced under good manufacturer practices (GMP) and rigorously controlled for quality by the marketing authorization holders (MAH). The present paper links poor-quality antimicrobials and AMR, highlighting examples of regulatory initiatives on this subject outside the EU, particularly those resulting from the World Health Organization (WHO) recommendations. It also intends to trigger a discussion on the role of such quality control programmes, particularly for antimicrobials, beyond the control at any stage of the quality parameters of a marketed medicine, to reflect whether or not it might be relevant to other regulatory coordinated actions against AMR.
Collapse
Affiliation(s)
- Helena Ponte
- INFARMED - Portuguese National Authority of Medicines and Health Products, IP Parque de Saúde de Lisboa, Av. do Brasil, 53, 1749-004, Lisboa, Portugal
| | - Rui Santos Ivo
- INFARMED - Portuguese National Authority of Medicines and Health Products, IP Parque de Saúde de Lisboa, Av. do Brasil, 53, 1749-004, Lisboa, Portugal
| | - Beatriz Silva-Lima
- iMed.UL - Research Institute for Medicines and Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003, Lisboa, Portugal
| | - Fernando Ramos
- REQUIMTE/LAQV - Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal.
| |
Collapse
|
8
|
Malmir M, Serrano R, Caniça M, Silva-Lima B, Silva O. A Comprehensive Review on the Medicinal Plants from the Genus Asphodelus. Plants (Basel) 2018; 7:E20. [PMID: 29534054 PMCID: PMC5874609 DOI: 10.3390/plants7010020] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 02/14/2018] [Revised: 03/05/2018] [Accepted: 03/10/2018] [Indexed: 12/12/2022]
Abstract
Abstract: Plant-based systems continue to play an essential role in healthcare, and their use by different cultures has been extensively documented. Asphodelus L. (Asphodelaceae) is a genus of 18 species and of a total of 27 species, sub-species and varieties, distributed along the Mediterranean basin, and has been traditionally used for treating several diseases particularly associated with inflammatory and infectious skin disorders. The present study aimed to provide a general review of the available literature on ethnomedical, phytochemical, and biological data related to the genus Asphodelus as a potential source of new compounds with biological activity. Considering phytochemical studies, 1,8-dihydroxyanthracene derivatives, flavonoids, phenolic acids and triterpenoids were the main classes of compounds identified in roots, leaf and seeds which were correlated with their biological activities as anti-microbial, anti-fungal, anti-parasitic, cytotoxic, anti-inflammatory or antioxidant agents.
Collapse
Affiliation(s)
- Maryam Malmir
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, 1649-003 Lisbon, Portugal.
| | - Rita Serrano
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, 1649-003 Lisbon, Portugal.
| | - Manuela Caniça
- Department of Infectious Diseases, National Reference Laboratory of Antibiotic Resistances and Healthcare Associated Infections, National Institute of Health Doutor Ricardo Jorge, 1649-016 Lisbon, Portugal.
| | - Beatriz Silva-Lima
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, 1649-003 Lisbon, Portugal.
| | - Olga Silva
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, 1649-003 Lisbon, Portugal.
| |
Collapse
|
9
|
de Mello-Sampayo C, Agripino AA, Stilwell D, Vidal B, Fernando AL, Silva-Lima B, Vaz MF, Canhão H, Marques MC. Chronic Hyperglycemia Modulates Rat Osteoporotic Cortical Bone Microarchitecture into Less Fragile Structures. Int J Endocrinol 2017; 2017:4603247. [PMID: 29081798 PMCID: PMC5610808 DOI: 10.1155/2017/4603247] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Revised: 06/28/2017] [Accepted: 07/13/2017] [Indexed: 11/28/2022] Open
Abstract
There is controversy concerning the diabetes impact on bone quality, notorious in type 2 diabetic postmenopausal women. One pointed cause might be uncontrolled glycemia. In this study, the effect of chronic hyperglycemia in bone turnover, morphology, and biomechanics was evaluated in female Wistar rats in the presence/absence of estrogens (ovariectomy). Animals (n = 28) were divided into sham, ovariectomized (OVX), hyperglycemic (streptozotocin 40 mg/kg, single-dose i.p.-STZ), and hyperglycemic-ovariectomized (STZ + OVX) animals. Blood biomarkers were estimated 60 days postovariectomy. Body weight, vertebral microarchitecture (L4-histomorphometry), femur biomechanical properties (bending tests), tibia ultrastructure (scanning electron microscopy), and femur and urinary calcium (atomic absorption) were also evaluated. The increased PINP/CTX ratio of hyperglycemic animals and the similar ratio between STZ + OVX and healthy animals contrasting with the lower ratio of OVX (in line with its histomorphometric data) suggest a tendency for improved bone formation in hyperglycemic-ovariectomized animals. The increased tibia medullar canal, which contrasts with the unaffected cortical thickness of both hyperglycemic groups while that of OVX decreased, was associated to the increased stiffness and strength of STZ + OVX bones compared to those of OVX, in line with the observed ultrastructure. Concluding, chronic hyperglycemia in ovariectomized female rats causes bone morphological changes that translate positively in the ultrastructure and mechanical properties of cortical bones.
Collapse
Affiliation(s)
- Cristina de Mello-Sampayo
- Department of Pharmacological Sciences, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
- Pharmacological and Regulatory Sciences, iMed, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
| | - Alaíde Alves Agripino
- Department of Pharmacological Sciences, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
- MEtRiCS, Unidade de Biotecnologia Ambiental (UBiA), Departamento de Ciências e Tecnologia da Biomassa, Faculdade de Ciências Tecnologia, Universidade Nova de Lisboa, Almada, Portugal
| | | | - Bruno Vidal
- Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
| | - Ana Luisa Fernando
- MEtRiCS, Unidade de Biotecnologia Ambiental (UBiA), Departamento de Ciências e Tecnologia da Biomassa, Faculdade de Ciências Tecnologia, Universidade Nova de Lisboa, Almada, Portugal
| | - Beatriz Silva-Lima
- Department of Pharmacological Sciences, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
- Pharmacological and Regulatory Sciences, iMed, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
| | - Maria Fátima Vaz
- IDMEC, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal
| | - Helena Canhão
- Nova Medical School and School of Public Health, Universidade Nova de Lisboa, Lisboa, Portugal
| | - M. Cristina Marques
- Department of Pharmacological Sciences, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
- MEtRiCS, Unidade de Biotecnologia Ambiental (UBiA), Departamento de Ciências e Tecnologia da Biomassa, Faculdade de Ciências Tecnologia, Universidade Nova de Lisboa, Almada, Portugal
| |
Collapse
|
10
|
de Mello-Sampayo C, Paterna A, Polizzi A, Duarte D, Batista I, Pinto R, Gonçalves P, Raymundo A, Batista AP, Gouveia L, Silva-Lima B, Bandarra NM. Evaluation of Marine Microalga Diacronema vlkianum Biomass Fatty Acid Assimilation in Wistar Rats. Molecules 2017; 22:molecules22071097. [PMID: 28671567 PMCID: PMC6152232 DOI: 10.3390/molecules22071097] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2017] [Revised: 06/22/2017] [Accepted: 06/27/2017] [Indexed: 01/19/2023] Open
Abstract
Diacronema vlkianum is a marine microalgae for which supposed health promoting effects have been claimed based on its phytochemical composition. The potential use of its biomass as health ingredient, including detox-shakes, and the lack of bioavailability studies were the main concerns. In order to evaluate the microalgae-biomass assimilation and its health-benefits, single-dose (CD1-mice) studies were followed by 66-days repeated-dose study in Wistar rats with the highest tested single-dose of microalgae equivalent to 101 mg/kg eicosapentaenoic acid + docosahexaenoic acid (EPA+DHA). Microalgae-supplementation modulated EPA and docosapentaenoic acid enrichment at arachidonic acid content expenditure in erythrocytes and liver, while increasing EPA content of heart and adipose tissues of rats. Those fatty acid (FA) changes confirmed the D. vlkianum-biomass FA assimilation. The principal component analyses discriminated brain from other tissues, which formed two other groups (erythrocytes, liver, and heart separated from kidney and adipose tissues), pointing to a distinct signature of FA deposition for the brain and for the other organs. The improved serum lipid profile, omega-3 index and erythrocyte plasticity support the cardiovascular benefits of D. vlkianum. These results bolster the potential of D. vlkianum-biomass to become a “heart-healthy” food supplement providing a safe and renewable source of bioavailable omega-3 FA.
Collapse
Affiliation(s)
- Cristina de Mello-Sampayo
- Department of Pharmacological Sciences, iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa, Lisbon 1649-003, Portugal.
| | - Angela Paterna
- Department of Pharmacological Sciences, iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa, Lisbon 1649-003, Portugal.
| | - Ambra Polizzi
- Department of Pharmacological Sciences, iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa, Lisbon 1649-003, Portugal.
| | - Diana Duarte
- Division of Aquaculture and Upgrading, Portuguese Institute for the Sea and Atmosphere (IPMA, IP), Rua Alfredo Magalhães Ramalho, Lisbon 1495-006, Portugal.
| | - Irineu Batista
- Division of Aquaculture and Upgrading, Portuguese Institute for the Sea and Atmosphere (IPMA, IP), Rua Alfredo Magalhães Ramalho, Lisbon 1495-006, Portugal.
| | - Rui Pinto
- Department of Pharmacological Sciences, iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa, Lisbon 1649-003, Portugal.
| | - Patrícia Gonçalves
- Division of Aquaculture and Upgrading, Portuguese Institute for the Sea and Atmosphere (IPMA, IP), Rua Alfredo Magalhães Ramalho, Lisbon 1495-006, Portugal.
| | - Anabela Raymundo
- LEAF (Linking Landscape Environment Agriculture and Food), Research Center. Instituto Superior de Agronomia, Universidade de Lisboa. Tapada da Ajuda, 1349-017 Lisbon, Portugal.
| | - Ana P Batista
- LEAF (Linking Landscape Environment Agriculture and Food), Research Center. Instituto Superior de Agronomia, Universidade de Lisboa. Tapada da Ajuda, 1349-017 Lisbon, Portugal.
| | - Luísa Gouveia
- LNEG_Bioenergy Unit, Estrada do Paço do Lumiar, 22, 1649-038 Lisbon, Portugal.
| | - Beatriz Silva-Lima
- Department of Pharmacological Sciences, iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa, Lisbon 1649-003, Portugal.
| | - Narcisa M Bandarra
- Division of Aquaculture and Upgrading, Portuguese Institute for the Sea and Atmosphere (IPMA, IP), Rua Alfredo Magalhães Ramalho, Lisbon 1495-006, Portugal.
- Interdisciplinary Centre of Marine and Environmental Research (CIIMAR/CIMAR), University of Porto, Rua dos Bragas 289, P 4050-123 Porto, Portugal.
| |
Collapse
|
11
|
Goldring C, Antoine DJ, Bonner F, Crozier J, Denning C, Fontana RJ, Hanley NA, Hay DC, Ingelman-Sundberg M, Juhila S, Kitteringham N, Silva-Lima B, Norris A, Pridgeon C, Ross JA, Sison Young R, Tagle D, Tornesi B, van de Water B, Weaver RJ, Zhang F, Park BK. Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury. Hepatology 2017; 65:710-721. [PMID: 27775817 PMCID: PMC5266558 DOI: 10.1002/hep.28886] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Accepted: 09/01/2016] [Indexed: 01/12/2023]
Abstract
Current preclinical drug testing does not predict some forms of adverse drug reactions in humans. Efforts at improving predictability of drug-induced tissue injury in humans include using stem cell technology to generate human cells for screening for adverse effects of drugs in humans. The advent of induced pluripotent stem cells means that it may ultimately be possible to develop personalized toxicology to determine interindividual susceptibility to adverse drug reactions. However, the complexity of idiosyncratic drug-induced liver injury means that no current single-cell model, whether of primary liver tissue origin, from liver cell lines, or derived from stem cells, adequately emulates what is believed to occur during human drug-induced liver injury. Nevertheless, a single-cell model of a human hepatocyte which emulates key features of a hepatocyte is likely to be valuable in assessing potential chemical risk; furthermore, understanding how to generate a relevant hepatocyte will also be critical to efforts to build complex multicellular models of the liver. Currently, hepatocyte-like cells differentiated from stem cells still fall short of recapitulating the full mature hepatocellular phenotype. Therefore, we convened a number of experts from the areas of preclinical and clinical hepatotoxicity and safety assessment, from industry, academia, and regulatory bodies, to specifically explore the application of stem cells in hepatotoxicity safety assessment and to make recommendations for the way forward. In this short review, we particularly discuss the importance of benchmarking stem cell-derived hepatocyte-like cells to their terminally differentiated human counterparts using defined phenotyping, to make sure the cells are relevant and comparable between labs, and outline why this process is essential before the cells are introduced into chemical safety assessment. (Hepatology 2017;65:710-721).
Collapse
Affiliation(s)
- Christopher Goldring
- MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
| | - Daniel J. Antoine
- MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
| | | | - Jonathan Crozier
- European Partnership for Alternative Approaches to Animal Testing (EPAA), Brussels, Belgium
| | - Chris Denning
- Department of Stem Cell Biology, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, UK
| | - Robert J. Fontana
- Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
| | - Neil A. Hanley
- Centre for Endocrinology & Diabetes, University of Manchester; Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre Manchester, UK
| | - David C. Hay
- MRC Centre for Regenerative Medicine, University of Edinburgh, UK
| | | | - Satu Juhila
- R&D, In Vitro Biology, Orion Pharma, Espoo, Finland
| | - Neil Kitteringham
- MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
| | | | - Alan Norris
- MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
| | - Chris Pridgeon
- MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
| | - James A. Ross
- MRC Centre for Regenerative Medicine, University of Edinburgh, UK
| | - Rowena Sison Young
- MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
| | - Danilo Tagle
- National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA
| | - Belen Tornesi
- Abbvie Global Pharmaceutical Research and Development, North Chicago, IL, USA
| | - Bob van de Water
- Faculty of Science, Leiden Academic Centre for Drug Research, Gorlaeus Laboratories, University of Leiden, Netherlands
| | - Richard J. Weaver
- Institut de Recherches Internationales Servier (I.R.I.S), Suresnes, 92284, Cedex France
| | - Fang Zhang
- MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
| | - B. Kevin Park
- MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
| |
Collapse
|
12
|
Cavaco MC, Pereira C, Kreutzer B, Gouveia LF, Silva-Lima B, Brito AM, Videira M. Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles. Eur J Pharm Biopharm 2017; 110:76-84. [DOI: 10.1016/j.ejpb.2016.10.024] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Revised: 09/21/2016] [Accepted: 10/30/2016] [Indexed: 01/10/2023]
|
13
|
Crommelin DJA, Broich K, Holloway C, Meesen B, Lizrova Preiningerova J, Prugnaud JL, Silva-Lima B. The regulator’s perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future? Mult Scler 2016; 22:47-59. [DOI: 10.1177/1352458516650744] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2016] [Accepted: 04/23/2016] [Indexed: 11/16/2022]
Abstract
Background: Although there is still no cure for multiple sclerosis (MS), the introduction of several innovative drugs with modes of action different from that of the existing drug arsenal and the progress in monitoring disease progression by imaging and using biomarkers are currently causing a knowledge surge. This provides opportunities for improving patient disease management. New therapies are also under development and pose challenges to the regulatory bodies regarding the optimal design of clinical trials with more patient-focused clinical endpoints. Moreover, with the upcoming patent expiry of some of the key first-line MS treatments in Europe, regulatory bodies will also face the challenge of recommending marketing authorisation for generic and abridged versions based on appropriate requirements for demonstrating equality/similarity to the innovator’s product. Objective: The goal of this article is to improve the understanding of the relevant guidance documents of the European Medicines Agency (EMA) on clinical investigation of medicinal products and to highlight the issues that the agency will need to clarify regarding follow-on products of first-line MS treatments. Conclusion: Today, it is clear that close collaboration between patients, healthcare professionals, regulatory bodies and industry is crucial for developing new safe and effective drugs, which satisfy the needs of MS patients.
Collapse
Affiliation(s)
- Daan JA Crommelin
- Department of Pharmaceutics, Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Sciences, Utrecht University, Utrecht, The Netherlands
| | - Karl Broich
- President and Head of the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Bonn, Germany
| | - Chris Holloway
- European Regulatory Consultant, Chief Scientific Officer of ERA Consulting GmbH, Walsrode, Germany
| | - Bianca Meesen
- Managing Director at Ismar Healthcare, Lier, Belgium
| | - Jana Lizrova Preiningerova
- Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Jean-Louis Prugnaud
- Expert Involved in the Development of Recommendations Related to Drug Registrations, Paris, France
| | - Beatriz Silva-Lima
- iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
| |
Collapse
|
14
|
Rocha J, Eduardo-Figueira M, Barateiro A, Fernandes A, Brites D, Bronze R, Duarte CMM, Serra AT, Pinto R, Freitas M, Fernandes E, Silva-Lima B, Mota-Filipe H, Sepodes B. Anti-inflammatory effect of rosmarinic acid and an extract of Rosmarinus officinalis in rat models of local and systemic inflammation. Basic Clin Pharmacol Toxicol 2015; 116:398-413. [PMID: 25287116 DOI: 10.1111/bcpt.12335] [Citation(s) in RCA: 161] [Impact Index Per Article: 17.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2014] [Accepted: 09/25/2014] [Indexed: 12/22/2022]
Abstract
Rosmarinic acid is a polyphenolic compound and main constituent of Rosmarinus officinalis and has been shown to possess antioxidant and anti-inflammatory properties. We aimed to evaluate the anti-inflammatory properties of rosmarinic acid and of an extract of R. officinalis in local inflammation (carrageenin-induced paw oedema model in the rat), and further evaluate the protective effect of rosmarinic acid in rat models of systemic inflammation: liver ischaemia-reperfusion (I/R) and thermal injury models. In the local inflammation model, rosmarinic acid was administered at 10, 25 and 50 mg/kg (p.o.), and the extract was administered at 10 and 25 mg/kg (equivalent doses to rosmarinic acid groups) to male Wistar rats. Administration of rosmarinic acid and extract at the dose of 25 mg/kg reduced paw oedema at 6 hr by over 60%, exhibiting a dose-response effect, suggesting that rosmarinic was the main contributor to the anti-inflammatory effect. In the liver I/R model, rosmarinic acid was administered at 25 mg/kg (i.v.) 30 min. prior to the induction of ischaemia and led to the significant reduction in the serum concentration of transaminases (AST and ALT) and LDH. In the thermal injury model, rosmarinic acid was administered at 25 mg/kg (i.v.) 5 min. prior to the induction of injury and significantly reduced multi-organ dysfunction markers (liver, kidney, lung) by modulating NF-κB and metalloproteinase-9. For the first time, the anti-inflammatory potential of rosmarinic acid has been identified, as it causes a substantial reduction in inflammation, and we speculate that it might be useful in the pharmacological modulation of injuries associated to inflammation.
Collapse
Affiliation(s)
- Joao Rocha
- iMed.ULisboa, Faculty of Pharmacy - University of Lisbon, Lisboa, Portugal
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Ponte H, Silva-Lima B, Ramos F. Sales of antibiotics for veterinary use in Portugal between 2006 and 2009. Int J Antimicrob Agents 2014; 44:567-8. [DOI: 10.1016/j.ijantimicag.2014.08.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Revised: 08/12/2014] [Accepted: 08/13/2014] [Indexed: 10/24/2022]
|
16
|
Erben RG, Silva-Lima B, Reischl I, Steinhoff G, Tiedemann G, Dalemans W, Vos A, Janssen RTA, Le Blanc K, van Osch GJVM, Luyten FP. White paper on how to go forward with cell-based advanced therapies in Europe. Tissue Eng Part A 2014; 20:2549-54. [PMID: 24749762 DOI: 10.1089/ten.tea.2013.0589] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The current White paper summarizes the discussions and exchange of experiences during the first European Interdisciplinary Summit on Cell-Based ATMPs held in Vienna, Austria, May 02-03, 2013. The meeting was supported by the Research Networking Programme REMEDIC (regenerative medicine) funded by the European Science Foundation and by the British Medical Research Council. To improve the competitiveness of Europe in the field of cell-based Advanced Medicinal Therapy Products (ATMPs), the following key issues were identified during the meeting: removal of national hurdles in the European Union, harmonization of national and subnational differences in Hospital Exemption rules, improved treatment algorithms for reimbursement, better knowledge on the mode of action, predictive preclinical efficacy and safety testing, need for innovative systems for preclinical testing, appropriate product characterization, manufacturing with cost of goods in mind, and appropriate design of clinical trials.
Collapse
Affiliation(s)
- Reinhold G Erben
- 1 Department of Biomedical Sciences, University of Veterinary Medicine , Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
de Mello-Sampayo C, Corvo ML, Mendes R, Duarte D, Lucas J, Pinto R, Batista AP, Raymundo A, Silva-Lima B, Bandarra NM, Gouveia L. Insights on the safety of carotenogenic Chlorella vulgaris in rodents. ALGAL RES 2013. [DOI: 10.1016/j.algal.2013.07.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
van Meer PJK, Kooijman M, Brinks V, Gispen-de Wied CC, Silva-Lima B, Moors EHM, Schellekens H. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs 2013; 5:810-6. [PMID: 23924803 DOI: 10.4161/mabs.25234] [Citation(s) in RCA: 92] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
The immunogenicity of biopharmaceuticals used in clinical practice remains an unsolved challenge in drug development. Non-human primates (NHPs) are often the only relevant animal model for the development of monoclonal antibodies (mAbs), but the immune response of NHPs to therapeutic mAbs is not considered to be predictive of the response in humans because of species differences. In this study, we accessed the drug registration files of all mAbs registered in the European Union to establish the relative immunogenicity of mAbs in NHPs and humans. The incidence of formation of antidrug-antibodies in NHPs and patients was comparable in only 59% of the cases. In addition, the type of antidrug-antibody response was different in NHP and humans in 59% of the cases. Humanization did not necessarily reduce immunogenicity in humans. Immunogenicity interfered with the safety assessment during non-clinical drug development when clearing or neutralizing antibodies were formed. While important to interpret the study results, immunogenicity reduced the quality of NHP data in safety assessment. These findings confirm that the ability to compare relative immunogenicity of mAbs in NHPs and humans is low. Furthermore, immunogenicity limits the value of informative NHP studies.
Collapse
Affiliation(s)
- Peter J K van Meer
- Utrecht Institute of Pharmaceutical Sciences; Department of Pharmaceutics; Utrecht University; Utretcht, the Netherlands
| | | | | | | | | | | | | |
Collapse
|
19
|
Duarte DM, Silva-Lima B. Paediatric studies for nationally authorised active substances: Revision of the published nonclinical juvenile animal studies. Reprod Toxicol 2012. [DOI: 10.1016/j.reprotox.2012.05.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
20
|
Duarte DM, Silva-Lima B. Nonclinical safety evaluation of anticancer medicines for paediatric population (PP): A role for juvenile animal studies? Reprod Toxicol 2011. [DOI: 10.1016/j.reprotox.2011.06.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
21
|
Duarte DM, Silva-Lima B. Juvenile animal studies in the development of pediatric medicines: experience from European medicines and pediatric investigation plans. Birth Defects Res B Dev Reprod Toxicol 2011; 92:353-358. [PMID: 21594973 DOI: 10.1002/bdrb.20299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2011] [Accepted: 04/06/2011] [Indexed: 05/30/2023]
Abstract
INTRODUCTION The need for early consideration of pediatric investigation plans (PIP) to support an indication in pediatric population has led to an increased focus on the relevance of nonclinical studies in juvenile animals (JAS). The usefulness of JAS is not yet established and a criterion for request is still a learning process. OBJECTIVE This article compares data from JAS in all medicines approved by European centralized procedure before Pediatric Regulation (1995-2005) and data from JAS in the nonclinical information on all approved PIP (2007-2009). RESULTS Of the 226 substances licensed by centralized procedure in 10 years, 31.9% were considered for children and 31 JAS were described in 9.7%. Since 2007, of the 205 PIP decisions, 50 PIP (24.3%) have 87 JAS planned or requested. The mean number of JAS in each medicine or PIP, increased from 1.4 to 1.7 between the two periods and the juvenile rat remained as the prevalent species. CONCLUSIONS Results demonstrate that JAS planned/performed in EU environment has significantly increased.
Collapse
Affiliation(s)
- Dinah M Duarte
- National Authority of Medicines and Health Products, I.P., Parque Saúde de Lisboa, Av. do Brasil 53, Lisbon, Portugal.
| | | |
Collapse
|
22
|
Silva-Lima B, Due Theilade-Thomsen M, Carleer J, Vidal JM, Tomasi P, Saint-Raymond A. Juvenile animal studies for the development of paediatric medicines: a description and conclusions from a European medicines agency workshop on juvenile animal testing for nonclinical assessors. ACTA ACUST UNITED AC 2010; 89:467-73. [DOI: 10.1002/bdrb.20257] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
23
|
Duarte DM, Silva-Lima B. Juvenile animal studies for the nonclinical safety evaluation of therapeutic monoclonal antibodies for the paediatric population: Revision of approved medicines in Europe for the last 15 years. Reprod Toxicol 2010. [DOI: 10.1016/j.reprotox.2010.05.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
24
|
Vidal JM, Kawabata TT, Thorpe R, Silva-Lima B, Cederbrant K, Poole S, Mueller-Berghaus J, Pallardy M, Van der Laan JW. In vitro cytokine release assays for predicting cytokine release syndrome: The current state-of-the-science. Report of a European Medicines Agency Workshop. Cytokine 2010; 51:213-5. [DOI: 10.1016/j.cyto.2010.04.008] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2010] [Accepted: 04/21/2010] [Indexed: 11/29/2022]
|
25
|
Silva-Lima B, Carlson D, Jones DR, Laurie D, Stahl E, Maria V, Janssens W, Robinson WT. The European and American use of exploratory approaches for first-in-human studies. Clin Transl Sci 2010; 3:38-41. [PMID: 20443952 DOI: 10.1111/j.1752-8062.2010.00174.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Exploratory approaches for first-in-human clinical studies have evolved over the last few years and have stimulated the issuance of national regulatory guidances in some European countries as well as the United States. With the increasing implementation of these approaches and the recent preparation of a multiregional regulatory guidance (ICH M3 rev2), an exchange of experiences on the opportunities and challenges of exploratory clinical trials was desirable; thus, a workshop focusing on the use of this clinical approach was planned and conducted in Lisbon, Portugal, March 18-19, 2009 sponsored by the Portuguese Health Authority (INFARMED) and DIA. The structure of the workshop focused in three main areas. Regulatory representatives from Portugal, Belgium, Germany, the United Kingdom and the United States formally reviewed their experiences. This was followed by a discussion on issues from an ethics review perspective as well as an insight to the opportunities in the area of biologics. The industry perspective was presented by representatives from Merck, Pfizer, J&J, Novartis, Speedel, AstraZeneca, GSK, and Roche. Finally, through break out sessions, issues were identified to be addressed moving forward. It is the purpose of this paper to report on the outcome of this workshop.
Collapse
|
26
|
Duarte DM, Silva-Lima B. On the need for juvenile animal studies in paediatric drug development: Experience from paediatric investigation plans. Reprod Toxicol 2009. [DOI: 10.1016/j.reprotox.2009.05.024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
27
|
Pinto R, Vieira C, Mota-Filipe H, Silva-Lima B. NaF may disturb male fertility in rodents. Toxicol Lett 1998. [DOI: 10.1016/s0378-4274(98)80850-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Mota-Filipe H, Luz-Rodrigues H, Silva-Lima B, Gia˜o J, Rico T. Indomethacin (IND) increases the no formation in the isolated perfused rat kidney (IPRK) and in human endothelial cells (HEC). Pharmacol Res 1995. [DOI: 10.1016/1043-6618(95)86507-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|